Timothy Yap, MD

M.D. Anderson Cancer Center

Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.

Registry trials as an overall official

all conditions, ClinicalTrials.gov

NIH grants tied to them

1 more share only the name and are not shown

Trial papers

PubMed author-name match

Trials

Studies that name Timothy Yap, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:47 UTC. Open this list on ClinicalTrials.gov

Ph1
NCT06130254 · Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers
M.D. Anderson Cancer Center · terminated · Advanced Solid Tumor, Non-small Cell Lung Cancers · principal investigator
Ph2
NCT05082025 · Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations
M.D. Anderson Cancer Center · terminated · Endometrial Cancer, Ovarian Cancer · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-11 23:47 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

Most cited trial papers

PubMed returned no clinical-trial papers for this author name.